Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$311.3m

Trevi Therapeutics Future Growth

Future criteria checks 0/6

Trevi Therapeutics is forecast to grow earnings and revenue by 10.8% and 95.6% per annum respectively while EPS is expected to grow by 18.3% per annum.

Key information

10.8%

Earnings growth rate

18.3%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate95.6%
Future return on equityn/a
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Trevi adds 19% on full data set from mid-stage cough study

Sep 19

Trevi Therapeutics: Moving Forward

Sep 11

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi has a new development chief

Feb 01

Earnings and Revenue Growth Forecasts

NasdaqGM:TRVI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261-64-71-549
12/31/2025N/A-58-59-579
12/31/2024N/A-50-48-449
9/30/2024N/A-44-35-35N/A
6/30/2024N/A-39-33-33N/A
3/31/2024N/A-34-34-34N/A
12/31/2023N/A-29-32-32N/A
9/30/2023N/A-27-32-32N/A
6/30/2023N/A-27-33-33N/A
3/31/2023N/A-28-29-29N/A
12/31/2022N/A-29-28-28N/A
9/30/2022N/A-32-28-28N/A
6/30/2022N/A-31-27-27N/A
3/31/2022N/A-33-28-28N/A
12/31/2021N/A-34-29-29N/A
9/30/2021N/A-35-32-32N/A
6/30/2021N/A-35-31-31N/A
3/31/2021N/A-33-32-32N/A
12/31/2020N/A-33-29-29N/A
9/30/2020N/A-30-26-26N/A
6/30/2020N/A-30-27-27N/A
3/31/2020N/A-29-24-24N/A
12/31/2019N/A-27-23-23N/A
9/30/2019N/A-28-22-22N/A
6/30/2019N/A-27-18-18N/A
3/31/2019N/A-27-19-18N/A
12/31/2018N/A-26-18-18N/A
9/30/2018N/A-22-16-16N/A
12/31/2017N/A-13N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRVI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRVI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRVI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRVI is forecast to have no revenue next year.

High Growth Revenue: TRVI is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRVI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:56
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trevi Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.